Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics (CORT) announced it will report its third quarter financial results on November 3, 2020. A corporate update will accompany the earnings report, alongside a conference call at 5:00 p.m. ET. To participate, attendees can register via a link or dial in using specified phone numbers. The replay of the call will be accessible until November 17, 2020. Corcept is focused on developing drugs for severe disorders by modulating cortisol's effects, with its approved drug Korlym® targeting Cushing’s syndrome, supported by a robust intellectual property portfolio.
- Scheduled announcement of Q3 financial results, potentially indicating stable or improving performance.
- Company's focus on drug development for severe disorders could drive future growth.
- None.
MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2020. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time.
Alternatively, you may dial 1-888-204-4368 from the United States or 1-313-209-4906 internationally approximately 15 minutes before the start of the call. The passcode will be 9018217.
A replay will be available through November 17, 2020 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 9018217.
About Corcept Therapeutics Incorporated
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.
CONTACT:
Christopher S. James, MD
Director, Investor Relations
Corcept Therapeutics
650-684-8725
cjames@corcept.com
www.corcept.com
FAQ
When will Corcept Therapeutics report their Q3 financial results?
What time is the Corcept Therapeutics conference call?
How can I participate in the Corcept Therapeutics conference call?
What is Korlym® used for?
